

BUCKET NO.: UNGR-1632

PATENT

1617  
IPW

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Evan C. Unger

Confirmation No.: 8641

Application No.: 10/084,855

Group Art Unit: 1617

Filing Date: February 27, 2002

Examiner: Shaham J. Sharareh

For: NOVEL ACOUSTICALLY ACTIVE DRUG DELIVERY SYSTEMS

DATE OF DEPOSIT: August 20, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

*Elizabeth A. McLoud*

TYPED NAME: Elizabeth A. McLoud

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☐ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

08/25/2004 RMEBRAHT 00000015 10084855

01 FC:1806

180.00 0P

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☒ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;

or

☒ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- ☐ Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).


## EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
- ☐ Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. \_\_\_\_\_, filed \_\_\_\_\_.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

- ☐ The relevance of those listed references which are not in the English language is as follows:
- ☒ There are no listed references which are not in the English language.

Date: 8/20/2004

  
Steven D. Maslowski  
Registration No. 46,905

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



Sheet 1 of 1

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. UNGR-1632	Application No. 10/084,855
		Applicant Evan C. Unger	
		Filing Date February 27, 2002	Group 1617
		Confirmation No. 5556	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	580	Goldberg, B.B., et al., "Ultrasound contrast agents: a review," <i>Ultrasound in Med. &amp; Biol.</i> , <b>1994</b> , 20(4), 319-333	
	581	Hansrani, P.K., et al., "The preparation and properties of sterile intravenous emulsions," <i>J. of Parenteral Science &amp; Technology</i> , <b>1983</b> , 37(4), 145-150	
	582	Szoka, F., Jr., et al., "comparative properties and methods of preparation of lipid vesicles (liposomes)," <i>Ann. Rev. Biophys. Bioeng.</i> , <b>1980</b> , 9, 467-508	
	583	Talsma, H., et al., "Liposomes as drug delivery systems, Part I: Preparation," <i>Pharmaceutical Technology</i> , <b>1992</b> , 96-106	
	584	Unger, E., et al., "Gas-filled lipid bilayers as ultrasound contrast agents," <i>Investigative Radiology</i> , 29(Suppl. 2), S134-S136	
	585	Unger, E., et al., "Gas filled lipid bilayers as imaging contrast agents," <i>J. of Liposome Res.</i> , <b>1994</b> , 4(2), 861-874	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	